HUMAN MONOCLONAL ANTIBODIES TARGETING SARS-COV-2
Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and bi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV and/or a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and bi-specific antibodies..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 23. Juni Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
TAN JOSHUA HOONG YU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-06-23, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 |
|---|
| Patentnummer: |
WO2022132904 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA013756567 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA013756567 | ||
| 003 | DE-627 | ||
| 005 | 20240308101712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA013756567 | ||
| 035 | |a (EPA)WO2022132904 | ||
| 035 | |a (EPA)80001354 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a TAN JOSHUA HOONG YU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HUMAN MONOCLONAL ANTIBODIES TARGETING SARS-COV-2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-06-23, Last update posted on www.tib.eu: 2024-03-07, Last updated: 2024-03-08 | ||
| 520 | |a Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and bi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV and/or a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and bi-specific antibodies. | ||
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CROMPTON PETER DOBBS |4 aut | |
| 700 | 0 | |a CHO HYESEON |4 aut | |
| 700 | 0 | |a GONZALES-WARTZ KRISTINA KAY |4 aut | |
| 700 | 0 | |a PETERSON MARY ELIZABETH |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 23. Juni |
| 773 | 1 | 8 | |g year:2022 |g day:23 |g month:06 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/80001354/publication/WO2022132904A1?q=WO2022132904 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 23 |c 06 | ||